

31 July 2026

Commercial momentum builds across both platform pillars

US wholesale channel scales, first NextLevel tablets ship, German distribution partner expected within weeks, and the NeuroStrip™ commercial footprint expands to 20 organisations across four countries.


Control Bionics Limited (ASX: CBL) (“Control Bionics” or “the Company”), a non-invasive neurotechnology platform company, today provides a business update on commercial progress across its Assistive Technology and NeuroTechnology Solutions strategic pillars. This update is provided in addition to, and should be read together with, the Company's Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026, released separately today.

Highlights

- The first NextLevel tablets have shipped, marking initial revenue from what the Company expects to be an important growth driver in FY27.
- NeuroStrip™: 20 organisations have now signed agreements across Australia, New Zealand, the United States and the United Kingdom, spanning elite sport, rehabilitation, clinical and research settings.
- Tobii Dynavox is extending its NeuroNode® rollout to additional US states, broadening the Company's wholesale reach.
- The next 10 PRC-Salttillo sales representatives will be onboarded in early August, with further representatives expected to be onboarded progressively through the balance of CY2026.
- Germany: following inclusion in the German Statutory Health Insurance Medical Aids Directory (HMDV) earlier this year, the Company expects to announce its first German distribution partner in the coming weeks, with rollout and onboarding already scheduled for later in August.
- A three-day UK market visit in June resulted in four signed agreements, with two further agreements expected shortly and six professional sporting clubs in active negotiation.
- In Japan independent interim clinical report from STROKE LAB Co., Ltd. in Japan, covering 31 measured participants, validates NeuroStrip as an objective assessment tool capable of detecting clinically meaningful muscle activity that conventional rehabilitation assessment could not capture.

CEO and Managing Director, Control Bionics Limited, Jeremy Steele said:

“What this update shows is momentum on both sides of the platform at the same time. Our wholesale partners in the US are extending their coverage and adding representatives, the first NextLevel tablets are out the door, and Germany is weeks away from having a partner on the ground. In parallel, NeuroStrip has gone from a small number of pilots to 20 signed organisations across four countries — including some of the most respected names in elite sport, rehabilitation and neurological research. Three days in the UK produced four signed agreements and a pipeline of six professional clubs. That is the clearest evidence yet that our strategic shift to a multi-application neurotechnology platform is working.”



Control Bionics Limited (ASX: CBL) | July 2026 Business Update

Pillar 1 - Assistive Technology

The Company's assistive technology business is transitioning from a direct retail model to a distributor-led wholesale model in North America, while extending its NeuroNode-only distribution model into European markets. Both workstreams progressed materially during and after the June quarter.

United States — wholesale channel scaling


Wholesale volumes through the Company's US distribution partners increased through June

and into July, and the Company expects this trend to build further as its two channel partners expand their coverage.

- Tobii Dynavox is extending its NeuroNode rollout to additional US states. Each state added expands the addressable funding and referral base available to the Company's largest US wholesale partner.
- PRC-Salttillo will onboard its next 10 sales representatives in early August. The Company expects onboarding to continue progressively across further representatives through the balance of 2026, deepening penetration of the PRC-Salttillo field force.
- The first NextLevel tablets have shipped. This is the initial revenue from the NextLevel iOS speech device program, which follows the Letter of Intent for 1,000 devices executed earlier in the year, and which the Company expects to be a meaningful contributor to FY27.

US WHOLESALE CHANNEL BUILD

Three distribution engines scaling in parallel through the balance of CY2026



US wholesale channel build — Tobii Dynavox, PRC and NextLevel scaling in parallel


Germany — European expansion

Following the awarding of HMV insurance coverage in Germany earlier this year, Control Bionics has been working to establish a distribution partner for the German market. The Company expects to announce its first German partner in the coming weeks, with rollout and onboarding already scheduled for later in August.

Germany represents the Company's first reimbursed European market and is the template for a capital-efficient, NeuroNode-only distribution model that the Company intends to extend into further European markets over time.

Pillar 2 — NeuroTechnology Solutions

NeuroStrip™ is the Company's wearable surface electromyography (sEMG) platform, delivering objective, non-invasive measurement of muscle activation for use in sports performance, rehabilitation, clinical and research settings. Commercial engagement has expanded rapidly, with 20 organisations across four countries now signed, predominantly under pilot and trial agreements. These trial arrangements range from 2-4 months and subject to successful completion of the trials the agreements will move into commercial paying arrangements.



NeuroStrip™ signed partner footprint by region and application segment. A further two UK agreements are expected shortly, with six professional sporting clubs in negotiation.

Australia and New Zealand

As part of its growing network of pilot partners, Control Bionics confirms that the following organisations have signed agreements to trial NeuroStrip across high-performance, rehabilitation and clinical settings during the recent period:

Organisation	Setting
Hawthorn Football Club	Elite sport — AFL
Brisbane Broncos	Elite sport — NRL
GWS GIANTS	Elite sport — AFL
Rugby Australia	Elite sport — national governing body
New Zealand Warriors	Elite sport — NRL
Royal Rehab	Rehabilitation

Better Rehab	Rehabilitation
Rocky Bay	Disability services and rehabilitation
Victoria University	Research and education

United States

The following US organisations have signed as customers or for initial trials:

Organisation	Setting
Mayo Clinic	Clinical and research
Barrow Neurological Institute	Clinical and neurological research
Mountain Land Physical Therapy	Rehabilitation
Ohio University	Research, sports performance and education
Hoop Hall	Elite and developmental sport
Club V South	Elite and developmental sport
Peak Performance	Performance training

The US pipeline continues to build, with further customer signings expected in the coming weeks.

United Kingdom

A short three-day trip to the United Kingdom in June demonstrated strong demand for the NeuroStrip solution. Four groups have already signed agreements, with a further two expected shortly. Each engagement commences with an initial two-month free trial before rolling into a commercial agreement.


Organisation	Setting
British Olympic Team / University of Nottingham	Elite sport and applied research
UK Sports Institute	High-performance sport
Meliora Medical	Rehabilitation and sports performance
Dr Tom Maden-Wilkinson	Applied research

All of these customers are expected to be live in the coming weeks. In addition we continue to work with a significant European Football Club, with announcement of this relationship to

follow. A further six professional sporting clubs are currently in negotiation to commence use of NeuroStrip.

UNITED KINGDOM — TRIAL TO COMMERCIAL PATHWAY

Outcome of a three-day UK market visit in June 2026



Clinical validation — STROKE LAB, Japan

STROKE LAB Co., Ltd., a Tokyo-based private-pay neurological rehabilitation facility specialising in stroke and Parkinson's disease, has released an independently authored interim report dated 30 June 2026 on its clinical use of NeuroStrip™, providing independent third-party evidence of the platform's clinical utility in routine practice. The report covers 31 participants over a six-month protocol with alternating intervention and assessment points.

STROKE LAB has integrated NeuroStrip into its evaluation workflow, using it alongside existing walking tests, balance scores, video assessment and rating scales. The facility reports that NeuroStrip enabled it to assess four things it had previously been unable to measure:


- Left/right asymmetry in muscle activity
- Timing of muscle contraction
- Propulsive force generation
- Presence of co-contraction

Key findings

Phase-specific sensitivity: Phase-by-phase analysis of the Timed Up and Go test (18 cases) found that increases in paretic-side engagement differed markedly by movement phase — 61% of cases showed increased engagement when sitting down, a weight-bearing task, compared with 28% when turning.

Timed Up and Go — phase-by-phase sEMG analysis (n = 18 cases)

Share of cases showing increased paretic-side engagement, by movement phase




Source: STROKE LAB Interim Report, 30 June 2026. Phase-level resolution of this kind is not available from a composite functional score.

Individual case evidence: In a chronic hemiplegia case (right putaminal haemorrhage, 2.5 years post-onset), eight weeks of direction-change training with multisensory sEMG feedback saw paretic-side medial gastrocnemius activity approximately double (13.7 → 27.4 μ V RMS), while the participant's Timed Up and Go improved 37% (31.3 → 19.7 seconds). A second case, following spinal ependymoma resection, showed a similar pattern: over two months of targeted home exercise, compensatory muscle activity fell approximately 71% while activity in the intended prime mover rose roughly fivefold, alongside improved patient-reported function.


Case 1 — chronic hemiplegia

Left side (paretic), 4 sessions over 8 weeks



Case 2 — home exercise prescription

Left side (paretic), 6 sessions over 2 months



Source: STROKE LAB Interim Report, 30 June 2026. Paretic-side surface EMG, pre- and post-intervention.

Function without full recovery: In nine chronic stroke patients walking independently without an orthosis at a functionally independent gait speed (median 0.90 m/s), NeuroStrip detected substantial bilateral asymmetry in lower-leg muscle activity — median 32% in tibialis anterior and 30% in medial gastrocnemius — that speed-based assessment alone would not reveal.

Commercial significance: The report demonstrates NeuroStrip delivering clinically actionable information in routine, fee-paying clinical practice rather than in a laboratory setting — the same value proposition the Company is taking to rehabilitation providers, high-performance sport and research institutions in Australia, the United States and the United Kingdom. STROKE LAB has identified three academic conference presentations arising from the work and intends to expand case volume, measure healthy controls to establish reference standards, and extend into biofeedback and education applications.

The company believes the opportunity in Stroke to be significant. In the US alone there are more than 800,000 individuals who would be appropriate for post-stroke rehab (per Morgan Stanley).

Important qualification: These are interim findings from a single centre. The report is observational, without a control group, randomisation or blinding, and has not been peer reviewed. The three academic conference presentations referred to are planned rather than delivered. The findings relate to the use of NeuroStrip as an objective assessment and biofeedback tool supporting therapist-delivered rehabilitation; they are not a clinical trial of NeuroStrip as a therapy and do not constitute evidence of therapeutic efficacy of the device itself. Functional improvements described arose from clinician-delivered intervention informed by NeuroStrip measurement.

Outlook

The Company enters the first quarter of FY27 with a clear set of near-term execution milestones across both pillars.

NEAR-TERM EXECUTION MILESTONES



Control Bionics remains focused on disciplined execution — converting the commercial groundwork of recent quarters into revenue, while managing costs and progressing towards its key strategic milestones.

Authorisation

This ASX announcement has been approved for release by the Board of Directors of Control Bionics Limited.

For further information, please contact:

Jeremy Steele

CEO and Managing Director

jsteele@controlbionics.com

Brett Crowley

Company Secretary

brettcrowley@controlbionics.com

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.

Forward-looking statements

This announcement contains certain forward-looking statements, including statements regarding anticipated partner onboarding, expected agreements, trial conversions and future revenue contribution. Forward-looking statements are based on the Company's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors, many of which are outside the Company's control. Trial and pilot agreements referred to in this announcement are non-binding evaluation arrangements which, unless otherwise stated, involve no committed minimum revenue and may not convert

into commercial agreements. Actual results may differ materially from those expressed or implied. The Company does not undertake to update any forward-looking statement except as required by law.

Clinical information: the STROKE LAB findings summarised in this announcement are interim, single-centre, observational results reported by a third party. They are not derived from a controlled or randomised clinical trial, have not been peer reviewed, and should not be interpreted as establishing the therapeutic efficacy or safety of any Control Bionics product. Nothing in this announcement should be read as a claim beyond the regulatory clearances held by the Company in the relevant jurisdiction.